Efficacy and Safety of Biphasic Insulin Aspart 30 for the Treatment of Type 2 Diabetes Mellitus

N/ACompletedNCT01542060

Novo Nordisk A/S298 enrolled

Overview

This study is conducted in Asia. The aim of this observational study is to collect efficacy and safety data of biphasic insulin aspart (NovoMix® 30) in type 2 diabetes under normal clinical practice conditions.

Study Type

OBSERVATIONAL

Enrollment

298

Conditions

Diabetes Diabetes Mellitus, Type 2

Interventions

biphasic insulin aspart 30DRUG

Administered via an insulin injection device. Dosages varied according to individual patients' medical requirement as determined by their attending clinician

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects from hospitals or clinics, diagnosed with type 2 diabetes mellitus

Locations (1)

Unnamed facility

Amman, Jordan

Outcomes

Primary Outcomes

HbA1c (glycosylated haemoglobin)

Secondary Outcomes

FBG (Fasting Blood Glucose)

Quality of life assessed through the WHO-DTSQ (World Health Organization-Diabetes Treatment Satisfaction Questionnaire)

Incidence of adverse events

Incidence of hypoglycaemic episodes

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.